CD201 Rat anti-Mouse, PE, Clone: 1560, BD
Rat Monoclonal Antibody
Supplier: BD Biosciences 566337
The 1560 monoclonal antibody specifically binds to CD201 which is also known as Endothelial protein C receptor (EPCR) or Activated protein C receptor (APC receptor). CD201 is encoded by Procr /(Protein C receptor, endothelial). CD201 is a ñ25 kDa single-pass type I transmembrane glycoprotein that binds both protein C and activated protein C (APC) and augments the activation of protein C by the thrombin-thrombomodulin/CD141 complex. APC functions as a serine protease that controls thrombin IIa generation by inhibiting factors Va and VIIIa. CD201 thus plays an essential role in preventing blood coagulation which may lead to tissue damage during sepsis and inflammatory responses. Procr /-gene deletion reportedly leads to embryonic lethality due to placental thrombosis. CD201 is expressed by endothelial cells with higher expression on large blood vessels. The 1560 monoclonal antibody can reportedly be used for the detection of bone marrow hematopoietic stem cells (HSC) which express high levels of CD201. A soluble form of CD201 which can bind protein C and APC has also been described.R-phycoerythrin (PE) is an accessory photosynthetic pigment found in red algae. It exists in vitro as a 240-kDa protein with 23 phycoerythrobilin chromophores per molecule. This makes PE one of the brightest fluorochromes for flow cytometry applications, but its photobleaching properties make it unsuitable for fluorescence microscopy.
|Procr, Epcr, APC receptor, Ccca, Centrocyclin, Ccd41|
|Mouse EPCR Recombinant Protein|
|Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.|
|Aqueous buffered solution containing ≤0.09% sodium azide.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok